Eventide Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Eventide Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-900,000	Closed	-$4.23M	–	311
2026 Q1	$4.23M	Buy	+900,000	New	+$4.57M	0.07%	170
2017 Q3	–	Sell	-150,000	Closed	-$2.33M	–	137
2017 Q2	$2.33M	Hold	150,000	–	–	0.14%	93
2017 Q1	$2.59M	Hold	150,000	–	–	0.17%	89
2016 Q4	$1.65M	Hold	150,000	–	–	0.11%	98
2016 Q3	$2.35M	Hold	150,000	–	–	0.14%	92
2016 Q2	$1.53M	Hold	150,000	–	–	0.09%	100
2016 Q1	$1.94M	Buy	150,000 +50,000	+50%	+$694K	0.11%	103
2015 Q4	$2.09M	Buy	+100,000	New	+$1.58M	0.1%	99

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Eventide Asset Management's CTMX Position: Q2 2026 in Review

Eventide Asset Management sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 900,000 shares — an estimated $4.23M sold.

Eventide Asset Management first reported a position in CTMX in Q4 2015 and held it in 8 quarters. The position peaked at $4.23M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Eventide Asset Management reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
Eventide Asset Management sold 900,000 CytomX Therapeutics shares in Q2 2026, an estimated $4.23M.
Eventide Asset Management first reported a position in CytomX Therapeutics in Q4 2015 and held it in 8 quarters.
Eventide Asset Management's CytomX Therapeutics position peaked at $4.23M in Q1 2026.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.